LSE:GSKPharmaceuticals
GSK China Drug Wins Connect Pipeline Progress With Valuation Debate
GSK (LSE:GSK) has secured key regulatory progress in China for two late stage therapies, bepirovirsen for chronic hepatitis B and Exdensur for severe asthma.
China’s National Medical Products Administration has accepted and approved these treatments, opening the door to broader use in large patient populations.
The decisions highlight real world validation of GSK’s specialty medicines pipeline and its focus on high impact disease areas.
For investors watching LSE:GSK, this update sits at...